Kinex Pharmaceuticals Initiates A Phase 2 Clinical Trial Of KX2-391 In Patients With Prostate Cancer
Kinex Pharmaceuticals opened a Phase 2 clinical trial to evaluate the safety and efficacy of KX2-391 in patients with bone-metastatic, castrate-resistant prostate cancer (CRPC) who have not had prior chemotherapy. The study will take place at the University of Chicago, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, the University of Wisconsin (Madison), the University …
Read more on Medical News Today
Novelos Therapeutics Pivotal Phase 3 Lung Cancer Trial Does Not Meet The Primary Survival Endpoint
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy …
Read more on Medical News Today